News Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ Continue Reading Previous Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B ProgramNext Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron Related Stories News Cheche Group Looks to Australia as Home Batteries Take on a Bigger Grid Role News Central New Energy (01735.HK) Receives MSCI Provisional ESG Rating of BB Under Semiconductor & Semiconductor Equipment Industry Model News Krait Critical Minerals Closes Second Tranche of Private Placement; Aggregate Proceeds Reach $1.51 Million News LinkDaddy Reports 1.52M AI Crawler Requests to AI Verified Registry News WentRogue Announces Public Experiment on Rogue AI Claims News June Announces Pet Grooming Software to Simplify Booking and Client Communication